Influenza vaccine effectiveness during the 2012 influenza season in Victoria, Australia: Influences of waning immunity and vaccine match

Journal of Medical Virology

Volumn 86, Issue 6, 2014, Pages 1017-1025

  Sullivan, Sheena G ^a   Komadina, Naomi ^a   Grant, Kristina ^b   Jelley, Lauren ^a   Papadakis, Georgina ^b   Kelly, Heath ^b,c  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c The Australian National University   (Australia)

Author keywords

Australia; Case test negative study; Influenza vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENETIC ANALYSIS; HEMAGGLUTINATION INHIBITION; HUMAN; INFANT; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; SCHOOL CHILD; VERY ELDERLY; VIRUS DETECTION; VIRUS ISOLATION; YOUNG ADULT; AMINO ACID SUBSTITUTION; EPIDEMIOLOGY; GENETICS; IMMUNOLOGY; INFLUENZA VIRUS A; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; SENTINEL SURVEILLANCE; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTIGENS, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SENTINEL SURVEILLANCE; TIME FACTORS; TREATMENT OUTCOME; VICTORIA; YOUNG ADULT;

EID: 84897966287     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23847     Document Type: Article

References (34)

1. Ansaldi F, Bacilieri S, Amicizia D, Valle L, Banfi F, Durando P, Sticchi L, Gasparini R, Icardi G, Crovari P. 2004. Antigenic characterisation of influenza B virus with a new microneutralisation assay: Comparison to haemagglutination and sequence analysis. J Med Virol 74:141-146.
2. Australian Government Department of Health and Ageing. Immunise Australia Program. Available at: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-influenza. [Accessed 09 Oct 2013].
3. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. 2011. Multiple imputation by chained equations: What is it and how does it work? Int J Methods Psychiatr Res 20:40-49.
4. Belongia EA, Kieke BA, Donahue JG, Coleman LA, Irving SA, Meece JK, Vandermause M, Lindstrom S, Gargiullo P, Shay DK. 2011. Influenza vaccine effectiveness in Wisconsin during the2007-08 season: Comparison of interim and final results. Vaccine 29:6558-6563.
5. Bragstad K, Emborg H, Kolsen Fischer T, Voldstedlund M, Gubbels S, Andersen B, Molbak K, Krause T. 2013. Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012/13-A rapid epidemiological and virological assessment. Euro Surveill 18: pii= 20397.
6. Cai Z, Zhang T, Wan XF. 2012. Antigenic distance measurements for seasonal influenza vaccine selection. Vaccine 30:448-4453.
7. Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, Garcia Cenoz M, Guevara M, Moran J, Irisarri F, Arriazu M, Albeniz E, Ezpeleta C, Barricarte A, Primary Health Care Sentinel N, Network for Influenza Surveillance in F Hospitals of N. 2013. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill pii= 18:20388.
8. Centers for Disease Control and Prevention. 2013. Interim adjusted estimates of seasonal influenza vaccine effectiveness-United States, february 2013. MMWR Morb Mortal Wkly Rep 62:119-1123.
9. De Serres G, Skowronski D, Wu X, Ambrose C. 2013. The test-negative design: Validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill 18: pii= 20585.
10. Fielding JE, Grant KA, Papadakis G, Kelly HA. 2011. Estimation of type- and subtype-specific influenza vaccine effectiveness in Victoria Australia using a test negative case control method 2007-2008. BMC Infect Dis 11:170.
11. Fielding J, Grant K, Tran T, Kelly H. 2012. Moderate influenza vaccine effectiveness in Victoria. Australia 2011. Euro Surveill 17: pii= 20115.
12. Foppa IM, Haber M, Ferdinands JM, Shay DK. 2013. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 31:3104-3109.
13. Hobson D, Curry RL, Beare AS, Ward-Gardner A. 1972. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70:767-777.
14. Jackson ML, Nelson JC. 2013. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 31:2165-2168.
15. Janjua N, Skowronski DM, De Serres G, Winter A, Dickinson JA, Mahmud SM, Gubbay J, Fonseca K, Charest H, Van Caeseele P, Crowcroft NS Fradet MD, Bastien N, Li Y, Krajden M, Sabaiduc S, Petric M. 2012. Component-Specific Estimates of 2011-2012 Influenza Vaccine Effectiveness Based on the Canadian Sentinel Surveillance System. 10th Canadian Immunization Conference. Vancouver, Canada, 3-5 Dec 2012. Available at: http://www.cicscolars.ca/abstract_view.php? abs_id=711715122 [Accessed 09 Oct 2013].
16. Kelly H, Barr I. 2009. Large trials confirm immunogenicity of H1N1 vaccines. Lancet 375:6-9.
17. Kelly HA, Sullivan SG, Grant KA, Fielding JE. 2013. Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64. years 2007-2011. Influenza Other Respi Viruses 7:729-737.
18. Kissling E, Valenciano M, I-MOVE Case-Control Studies Team. 2012. Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: Results from the I-MOVE multicentre case-control study, 2011/12. Euro Surveill 17: pii= 20146.
19. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen J, Nunes B, Pitigoi D, Rizzo C, Rebolledo J, Paradowska-Stankiewicz I, Jimenez-Jorge S, Horvath J, Daviaud I, Guiomar R, Necula G, Bella A, OD J, Gluchowska M, Ciancio B, Nicoll A, Moren A. 2013. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: Results from the I-MOVE multicentre case-control study. Euro Surveill 18: pii= 20390.
20. Medeiros R, Escriou N, Naffakh N, Manuguerra JC, van der Werf S. 2001. Hemagglutinin residues of recent human A(H3N2) influenza viruses that contribute to the inability to agglutinate chicken erythrocytes. Virology 289:74-85.
21. Nichol KL. 2008. Efficacy and effectiveness of influenza vaccination. Vaccine 26:D17-D22.
22. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, Orenstein WA. 2007. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol 36:623-631.
23. Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson C, Robertson C, Cottrell S, Smyth B, Zambon M, Moore C, Fleming D, Watson J. 2013. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: Evidence of waning intra-seasonal protection. Euro Surveill 18: pii= 20389.
24. Skowronski DM, Tweed SA, De Serres G. 2008. Rapid decline of influenza vaccine-induced antibody in the elderly: Is it real, or is it relevant? J Infect Dis 197:490-502.
25. Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, Gardy JL, Gubbay J, Fonseca K, Charest H, Crowcroft NS, Fradet MD, Bastien N, Li Y, Krajden M, Sabaiduc S, Petric M. 2012. A Sentinel Platform to Evaluate Influenza Vaccine Effectiveness and New Variant Circulation Canada 2010-2011. Season. Clin Infect Dis 55:332-342.
26. Skowronski D, Janjua N, De Serres G, Dickinson J, Winter A, Mahmud S, Sabaiduc S, Gubbay J, Charest H, Petric M, Fonseca K, Van Caeseele P, Kwindt T, Krajden M, Eshaghi A, Li Y. 2013. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada s sentinel surveillance network January 2013. Euro Surveill 18: pii= 20394.
27. Sullivan SG, Tay EL, Kelly H. 2013. Variable definitions of the influenza season and their impact on vaccine effectiveness estimates. Vaccine 31:4280-4283.
28. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEG A5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731-2739.
29. Thursky K, Cordova SP, Smith D, Kelly H. 2003. Working towards a simple case definition for influenza surveillance. J Clin Virol 27:170-179.
30. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, Tashkandi M, Bauch CT, Loeb M. 2013. Comparing influenza vaccine efficacy against mismatched and matched strains: A systematic review and meta-analysis. BMC Med 11:153.
31. Valenciano M, Kissling E, I-Move Case-Control Study Team. 2013. Early estimates of seasonal influenza vaccine effectiveness in Europe: Results from the I-MOVE multicentre case-control study, 2012/13. Euro Surveill 18: pii= 20400.
32. WHO Collaborating Centre for Influenza at CDC Atlanta. CDC protocol of realtime RTPCR for influenza A(H1N1). Available at: http://www.who.int/csr/resources/publications/swineflu/realtimeptpcr/en/ [Accessed 25 Mar 2013].
33. WHO Consultation and Information Meeting on the Composition of Influenza Virus Vaccines for the Northern Hemisphere 2013-2014. Recommended composition of influenza virus vaccines for use in the 2013-214 northern hemisphere influenza season. Available at: http://www.who.int/influenza/vaccines/virus/recommendations/2013_14_north/en/ [Accessed 8 Mar 2013].
34. Wilson IA, Cox NJ. 1990. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 8:737-771.